Compare Stocks: INDV, NBIX, JAZZ, and CORT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CORT Corcept Therapeutics	$114.47 +3.6%	$93.34	$28.66 ▼ $122.21	$11.95B	0.45	1.33 million shs	728,888 shs
INDV Indivior	$39.01 +2.1%	$39.55	$22.22 ▼ $42.81	$4.51B	0.86	2.42 million shs	988,383 shs
JAZZ Jazz Pharmaceuticals	$244.96 -0.4%	$242.80	$116.53 ▼ $265.05	$15.96B	0.32	815,200 shs	542,030 shs
NBIX Neurocrine Biosciences	$152.72 +1.3%	$167.98	$122.14 ▼ $186.12	$15.33B	0.39	1.45 million shs	1.31 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CORT Corcept Therapeutics	+3.58%	+3.34%	+27.80%	+103.07%	+57.24%
INDV Indivior	+2.07%	+0.49%	-4.69%	+6.12%	+69.83%
JAZZ Jazz Pharmaceuticals	-0.36%	-4.52%	+2.36%	+7.08%	+109.15%
NBIX Neurocrine Biosciences	+1.26%	-6.54%	-11.24%	-3.60%	+16.03%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CORT Corcept Therapeutics	$114.47 +3.6%	$93.34	$28.66 ▼ $122.21	$11.95B	0.45	1.33 million shs	728,888 shs
INDV Indivior	$39.01 +2.1%	$39.55	$22.22 ▼ $42.81	$4.51B	0.86	2.42 million shs	988,383 shs
JAZZ Jazz Pharmaceuticals	$244.96 -0.4%	$242.80	$116.53 ▼ $265.05	$15.96B	0.32	815,200 shs	542,030 shs
NBIX Neurocrine Biosciences	$152.72 +1.3%	$167.98	$122.14 ▼ $186.12	$15.33B	0.39	1.45 million shs	1.31 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CORT Corcept Therapeutics	+3.58%	+3.34%	+27.80%	+103.07%	+57.24%
INDV Indivior	+2.07%	+0.49%	-4.69%	+6.12%	+69.83%
JAZZ Jazz Pharmaceuticals	-0.36%	-4.52%	+2.36%	+7.08%	+109.15%
NBIX Neurocrine Biosciences	+1.26%	-6.54%	-11.24%	-3.60%	+16.03%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CORT Corcept Therapeutics	2.63	Moderate Buy	$119.17	4.10% Upside
INDV Indivior	2.86	Moderate Buy	$45.17	15.78% Upside
JAZZ Jazz Pharmaceuticals	3.00	Buy	$272.89	11.40% Upside
NBIX Neurocrine Biosciences	2.88	Moderate Buy	$200.86	31.52% Upside

Current Analyst Ratings Breakdown

Latest INDV, NBIX, JAZZ, and CORT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	NBIX Neurocrine Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$196.00 ➝ $182.00
8/11/2026	NBIX Neurocrine Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
8/11/2026	JAZZ Jazz Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$280.00 ➝ $283.00
8/7/2026	INDV Indivior	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/5/2026	INDV Indivior	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$46.00 ➝ $43.00
8/4/2026	JAZZ Jazz Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Buy (B-)
8/4/2026	INDV Indivior	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$53.00
8/4/2026	JAZZ Jazz Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$287.00
8/4/2026	JAZZ Jazz Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$275.00 ➝ $300.00
8/4/2026	JAZZ Jazz Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$254.00 ➝ $264.00
8/4/2026	JAZZ Jazz Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$315.00

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CORT Corcept Therapeutics	$761.41M	16.25	$0.94 per share	122.42	$6.53 per share	17.53
INDV Indivior	$1.24B	3.72	$2.78 per share	14.05	($1.76) per share	-22.16
JAZZ Jazz Pharmaceuticals	$4.27B	3.73	$16.20 per share	15.12	$73.97 per share	3.31
NBIX Neurocrine Biosciences	$2.86B	5.43	$5.08 per share	30.09	$36.34 per share	4.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CORT Corcept Therapeutics	$99.65M	$0.42	272.55	48.71	N/A	6.52%	8.26%	6.45%	11/3/2026 (Estimated)
INDV Indivior	$210M	$2.79	13.98	10.19	N/A	26.65%	-283.11%	36.85%	10/29/2026 (Estimated)
JAZZ Jazz Pharmaceuticals	-$356.15M	$14.50	16.89	11.00	0.22	20.45%	33.97%	13.02%	N/A
NBIX Neurocrine Biosciences	$478.60M	$6.82	22.39	15.70	0.53	20.91%	22.43%	15.64%	10/27/2026 (Estimated)

Latest INDV, NBIX, JAZZ, and CORT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/3/2026	Q2 2026 & Merger	INDV Indivior	$0.8690	$1.15	+$0.2810	$4.90	$306.23 million	$343.00 million
8/3/2026	Q2 2026	JAZZ Jazz Pharmaceuticals	$6.18	$5.71	-$0.47	$2.78	$1.11 billion	$1.21 billion
7/29/2026	Q2 2026	CORT Corcept Therapeutics	$0.0243	$0.36	+$0.3357	$0.36	$221.15 million	$256.15 million
6/30/2026	Q2 2026	INDV Indivior	N/A	$5.75	N/A	$4.90	N/A	$343.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CORT Corcept Therapeutics	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NBIX Neurocrine Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CORT Corcept Therapeutics	N/A	2.86	2.77
INDV Indivior	N/A	0.84	0.66
JAZZ Jazz Pharmaceuticals	0.69	1.78	1.58
NBIX Neurocrine Biosciences	N/A	1.87	1.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CORT Corcept Therapeutics	93.61%
INDV Indivior	60.33%
JAZZ Jazz Pharmaceuticals	89.14%
NBIX Neurocrine Biosciences	92.59%

Insider Ownership

Company	Insider Ownership
CORT Corcept Therapeutics	20.70%
INDV Indivior	0.74%
JAZZ Jazz Pharmaceuticals	4.10%
NBIX Neurocrine Biosciences	4.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CORT Corcept Therapeutics	300	108.10 million	85.72 million	Optionable
INDV Indivior	1,051	118.01 million	117.14 million	Not Optionable
JAZZ Jazz Pharmaceuticals	2,890	64.92 million	62.25 million	Optionable
NBIX Neurocrine Biosciences	2,000	101.65 million	96.97 million	Optionable

INDV, NBIX, JAZZ, and CORT Headlines

Recent News About These Companies

Summit Global Investments Invests $4.96 Million in Neurocrine Biosciences, Inc. $NBIX

August 15 at 6:55 AM | marketbeat.com

Morgan Stanley Has Lowered Expectations for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price

August 13 at 10:53 AM | marketbeat.com

NBIX stock slips as $2.9B Soleno deal triggers fresh drug safety warnings

August 13 at 9:05 AM | msn.com

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Recommendation of "Moderate Buy" from Analysts

August 13 at 2:29 AM | americanbankingnews.com

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Consensus Rating of "Moderate Buy" by Brokerages

August 13 at 2:28 AM | marketbeat.com

What's going on with Neurocrine Biosciences stock on Wednesday?

August 12 at 6:58 PM | msn.com

Why Neurocrine Biosciences (NBIX) Stock Is Down Today

August 12 at 2:50 PM | quiverquant.comQ

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily ...

August 12 at 1:57 PM | aol.comA

Neurocrine Biosciences shares fall amid Vykat safety concerns

August 12 at 1:57 PM | msn.com

Neurocrine slips as safety issues linked to Vykat XR resurface

August 12 at 8:56 AM | seekingalpha.com

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

August 12 at 8:30 AM | prnewswire.com

Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug

August 12 at 7:12 AM | reuters.com

Handelsbanken Fonder AB Has $34.70 Million Holdings in Neurocrine Biosciences, Inc. $NBIX

August 12 at 5:43 AM | marketbeat.com

Bank of America Corp DE Boosts Holdings in Neurocrine Biosciences, Inc. $NBIX

August 10, 2026 | marketbeat.com

Assenagon Asset Management S.A. Has $37.52 Million Holdings in Neurocrine Biosciences, Inc. $NBIX

August 9, 2026 | marketbeat.com

Neurocrine Biosciences (NASDAQ:NBIX) Lowered to Hold Rating by Wall Street Zen

August 9, 2026 | americanbankingnews.com

Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Lowered by Wall Street Zen

August 9, 2026 | marketbeat.com

Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Cetera Investment Advisers

August 8, 2026 | marketbeat.com

Neurocrine Biosciences Begins Phase 1 Trial of Obesity Drug Candidate

August 7, 2026 | finance.yahoo.com

Neurocrine Biosciences, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 7, 2026 | seekingalpha.com

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist

August 7, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDV, NBIX, JAZZ, and CORT Company Descriptions

Corcept Therapeutics NASDAQ:CORT

$114.47 +3.96 (+3.58%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$114.66 +0.19 (+0.16%)

As of 08/14/2026 07:34 PM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Indivior NASDAQ:INDV

$39.01 +0.79 (+2.07%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$39.00 -0.01 (-0.03%)

As of 08/14/2026 07:36 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Jazz Pharmaceuticals NASDAQ:JAZZ

$244.96 -0.89 (-0.36%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$245.24 +0.28 (+0.12%)

As of 08/14/2026 07:56 PM Eastern

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Neurocrine Biosciences NASDAQ:NBIX

$152.72 +1.90 (+1.26%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$152.78 +0.06 (+0.04%)

As of 08/14/2026 07:57 PM Eastern

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INDV, NBIX, JAZZ, and CORT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INDV, NBIX, JAZZ, and CORT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INDV, NBIX, JAZZ, and CORT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDV, NBIX, JAZZ, and CORT Company Descriptions

Corcept Therapeutics NASDAQ:CORT

Indivior NASDAQ:INDV

Jazz Pharmaceuticals NASDAQ:JAZZ

Neurocrine Biosciences NASDAQ:NBIX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INDV, NBIX, JAZZ, and CORT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INDV, NBIX, JAZZ, and CORT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INDV, NBIX, JAZZ, and CORT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDV, NBIX, JAZZ, and CORT Company Descriptions

Corcept Therapeutics NASDAQ:CORT

Indivior NASDAQ:INDV

Jazz Pharmaceuticals NASDAQ:JAZZ

Neurocrine Biosciences NASDAQ:NBIX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools